Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772527 | 1.00 | CYP1A2 (0.36) | CYP1A2SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4355400 | 0.81 | LMNA (0.40) | CYP1A2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4355397 | 0.81 | LMNA (0.40) | CYP1A2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL952570 | 0.80 | ALDH1A1 (0.38) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL20657251 | 0.78 | MEN1 (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL20657212 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL2616395 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2AALDH1A1GAALMNA | |
| SCHEMBL4720287 | 0.75 | MEN1 (0.37) | CYP1A2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL28290750 | 0.75 | L3MBTL1 (0.41) | CYP1A2SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15864693 | 0.72 | CYP1A2 (0.41) | CYP1A2SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | CYP1A2 135/4885SMN1; SMN2 2680/4885MEN1 901/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | CYP1A2 559/4885SMN1; SMN2 2906/4885MEN1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.